# A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects

> **NCT07479576** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 190 (estimated)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** QL2106
- **DRUG:** Tremfye®

## Key facts

- **NCT ID:** NCT07479576
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-11-10
- **Primary completion:** 2026-04-12
- **Final completion:** 2026-08-30
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07479576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07479576, "A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07479576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*